HCPCS code J9041: Bortezomib (Velcade) billing guide 2026

Key Takeaways

HCPCS code J9041 describes Injection, bortezomib (Velcade), 0.1 mg, billed per 0.1 mg unit administered.

J9041 is reserved for brand-name Velcade only. J9044 was deleted effective 12/31/2022; non-Velcade bortezomib now requires the manufacturer-specific code matching the NDC (J9046, J9048, J9049, or J9051).

CMS designates J9041 as a single-dose container code, requiring JW or JZ modifier attachment on every claim since JZ reporting became mandatory July 1, 2023.

Pabau’s claims management software helps oncology billing teams track drug units, apply modifiers, and reduce claim denials.

HCPCS code J9041 is the billing code for Injection, bortezomib (Velcade), 0.1 mg — a proteasome inhibitor chemotherapy drug given by IV or subcutaneous injection for multiple myeloma and mantle cell lymphoma. Each 0.1 mg administered equals one billable unit, and every claim needs a JW or JZ modifier, a covered ICD-10-CM diagnosis, and the correct manufacturer-specific code when the product isn’t brand-name Velcade.

This guide covers code properties, dosage and unit calculation, JW/JZ modifier rules, related bortezomib codes, Medicare reimbursement, and prior authorization requirements for J9041 claims.

HCPCS code J9041: Definition, code description, and clinical context

HCPCS code J9041 describes “Injection, bortezomib (Velcade), 0.1 mg,” a chemotherapy drug code maintained by CMS under the HCPCS Level II code set. Claims management software built for high-cost drug billing helps oncology teams track administered units, apply the right modifiers, and catch errors before submission.

Bortezomib, marketed under the brand name Velcade by Janssen, received FDA approval in 2003. It is classified as a proteasome inhibitor (major drug class: 26S proteasome) and is administered by intravenous or subcutaneous injection, not orally. The code is active for 2026 and applies exclusively to the Velcade brand formulation.

Code properties at a glance

Clinical indications for bortezomib (J9041)

Understanding why a drug is prescribed matters for documentation and medical necessity. Bortezomib is FDA-approved for two primary indications: multiple myeloma and mantle cell lymphoma. Accurate ICD-10-CM diagnosis coding linked to one of these approved indications is essential for claim acceptance.

Pabau’s patient intake software helps oncology teams capture structured clinical documentation at the point of care, making it easier to pull the right diagnosis codes before a claim is submitted. Thorough medical forms and documentation practices reduce the risk of medical necessity denials for high-cost drugs like bortezomib.

ICD-10-CM diagnosis codes commonly linked to J9041

• C90.00 – Multiple myeloma, not having achieved remission
• C90.01 – Multiple myeloma in remission
• C90.02 – Multiple myeloma in relapse
• C83.10 – Mantle cell lymphoma, unspecified site
• C83.11 – Mantle cell lymphoma, lymph nodes of head, face, and neck

Payer coverage decisions for J9041 are often guided by local coverage determinations (LCDs) within the CMS Medicare Coverage Database. Coders should verify the applicable LCD for their jurisdiction before submitting claims for off-label or less common indications.

How to bill HCPCS code J9041: Dosage calculation and units

Most billing errors on J9041 stem from miscalculating units. The code is billed per 0.1 mg of bortezomib administered. A dose of 1.0 mg is therefore billed as 10 units; a dose of 2.5 mg is billed as 25 units. Bill only for the actual amount administered to the patient, not the full vial contents if there is waste.

This distinction between administered dose and vial contents is where the JW and JZ modifier requirements become critical (covered in the next section). Accurate unit calculation is also why many oncology practices integrate their infusion documentation directly with their practice management software to prevent rounding errors from manual entry.

Administration CPT codes to pair with J9041

J9041 covers the drug cost only. The administration of bortezomib requires a separate CPT code reported on the same claim:

• CPT 96409 – Chemotherapy administration; intravenous push, single or initial substance/drug
• CPT 96413 – Chemotherapy administration; intravenous infusion technique, up to 1 hour
• CPT 96401 – Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic (used when bortezomib is given subcutaneously)

Check NCCI (National Correct Coding Initiative) edits before pairing administration codes to ensure no bundling conflicts apply to your specific claim scenario.

JW and JZ modifier requirements for HCPCS code J9041

CMS has designated J9041 as a single-dose container code, which carries a compliance obligation. JZ reporting was voluntary starting January 1, 2023, and became mandatory July 1, 2023. Since that date, CMS policy requires that one of two modifiers be appended to every J9041 claim:

• JW modifier – Indicates drug wastage occurred. Use when bortezomib from a single-dose vial was discarded after the patient’s dose was drawn. The discarded amount is separately billed with the JW modifier to document waste.
• JZ modifier – Indicates no drug wastage occurred. Use when the full vial contents were administered with no discard.

Failure to append one of these modifiers can result in claim rejection or audit exposure. The CMS JW/JZ Modifier Policy documentation provides the official code-level designation. Billing teams using patient management software that supports chemotherapy drug tracking can set up modifier prompts to reduce the risk of forgetting this requirement at claim submission.

JW vs. JZ: A practical example

A patient receives a 2.0 mg dose of Velcade. The vial contains 3.5 mg. The administered dose (20 units) is billed as J9041 x 20 with modifier JW.

The wasted 1.5 mg (15 units) is reported separately as J9041 x 15, also with modifier JW, to reflect the discarded amount. If the full vial were administered with no waste, modifier JZ would replace JW on the single line item.

Streamline oncology drug billing with Pabau

Pabau's claims management tools help oncology and infusion practices track administered drug units, apply required modifiers, and submit cleaner claims. See how it works for high-cost drug billing workflows.

Book a demo

J9041 vs. J9046, J9047, J9048, J9049, and J9051: Related bortezomib codes

The existence of multiple bortezomib codes is a common source of claim errors, especially since J9044 — formerly the catch-all code for non-Velcade bortezomib — was deleted effective December 31, 2022.

Each active code maps to a specific manufacturer’s product and carries explicit CMS guidance on when it applies. These codes are not therapeutically equivalent per CMS, which means you cannot freely substitute one for another.

J9044 (Injection, bortezomib NOS) was deleted effective December 31, 2022. For dates of service on or after January 1, 2023, non-Velcade bortezomib must be billed with the manufacturer-specific code matching the product’s NDC: J9046 (Dr. Reddy’s), J9048 (Fresenius Kabi), J9049 (Hospira), or J9051 (Maia, added October 1, 2023).

Using J9041 — or the deleted J9044 — for a non-Velcade product is a coding error that can trigger claim denial or audit findings.

EHR integration with your billing workflow auto-populates the dispensed product’s NDC and matches it to the correct J code, removing the manual lookup step that most often causes this error.

Medicare reimbursement and fee schedule for J9041

Medicare Part B reimburses physician-administered drugs under the buy-and-bill model of medical billing at Average Sales Price (ASP) plus 6%. Because ASP rates are updated quarterly by CMS, any specific dollar figure cited here would be outdated within weeks.

Practices should query the current ASP rate directly from the CMS Physician Fee Schedule lookup tool or use a current HCPCS code reference via AAPC Codify for the most recent quarterly figures.

The ASP + 6% model applies when bortezomib is purchased and administered in a physician’s office or outpatient infusion center (the buy-and-bill model). If a specialty pharmacy dispenses the drug and bills separately, reimbursement follows the pharmacy’s contracted rate under Part D or a commercial plan benefit, which differs from Part B payment rules.

Buy-and-bill vs. specialty pharmacy considerations

Oncology practices face a choice on high-cost injectables: purchase the drug inventory directly (buy-and-bill) or refer patients to a specialty pharmacy. Each approach affects billing codes, reimbursement pathways, and cash flow differently.

• Buy-and-bill: Practice purchases Velcade, administers it, and bills J9041 to Medicare Part B at ASP + 6%. The practice carries inventory risk but captures the spread between acquisition cost and the ASP payment.
• Specialty pharmacy: Pharmacy owns and bills the drug cost; the practice bills only the administration CPT code. Reduces inventory and cash flow risk but eliminates the ASP + 6% drug margin. This is similar to the billing structure for HCPCS code S9542, which covers per diem home injectable therapy dispensed outside the practice.
• Payer-specific rules: Commercial plans may mandate specialty pharmacy dispensing for high-cost biologics regardless of the practice’s preference. Verify each plan’s drug benefit design before assuming buy-and-bill is an option.

Prior authorization requirements for J9041

Prior authorization (PA) requirements for J9041 vary significantly by payer and plan type. Medicare fee-for-service generally does not require PA for chemotherapy drugs covered under Part B, but Medicare Advantage plans frequently impose their own PA requirements. Commercial payers and Medicaid managed care organizations typically require PA for high-cost oncology drugs.

Effective practice management software features that support prior authorization tracking can materially reduce treatment delays for oncology patients. A denied PA that delays a chemotherapy cycle affects both patient care and reimbursement timelines. Practices should build a PA workflow that initiates authorization requests before the scheduled administration date, not the day of infusion.

Documentation needed to support a PA request for bortezomib

• Confirmed diagnosis (multiple myeloma or mantle cell lymphoma) with staging documentation
• Pathology or biopsy report confirming the diagnosis
• Treatment line (first-line vs relapsed/refractory) and prior therapies attempted
• ECOG or Karnofsky performance status
• Planned regimen, cycle number, and dosing schedule
• Prescribing oncologist’s letter of medical necessity where required by the payer

Keep this documentation in the patient’s chart and ensure it is retrievable for HIPAA-compliant medical office documentation standards. Payers conducting retrospective audits on high-cost drug claims will request the original PA approval, the claim superbill, and supporting clinical documentation.

Other high-cost oncology and hematology injectables follow similar PA and modifier rules. See our guides to HCPCS code J9145 for daratumumab (Darzalex) and HCPCS code J2329 for ublituximab-xiiy (Briumvi) if your practice bills multiple monoclonal antibody or proteasome inhibitor therapies.

Managing J9041 claims in oncology practice management software

Chemotherapy drug billing differs from standard office visit billing in several ways that generic practice management tools are not built to handle. High per-unit drug costs amplify the financial impact of any modifier error, unit miscalculation, or code mismatch. A system that surfaces these risk points before submission is worth far more than one that processes clean claims passively.

Pabau’s prescription management software supports structured drug documentation that feeds directly into billing workflows. For oncology and infusion practices, this means administered dose data is captured at the clinical level and available to billing staff without re-entry. Manual transcription between infusion records and billing forms is one of the most preventable sources of unit errors on J9041 claims.

The broader category of medical practice management software increasingly supports oncology-specific workflows, including modifier prompts, NDC capture, and prior authorization tracking. When evaluating a system for an infusion or hematology/oncology practice, look specifically for these capabilities rather than relying on general-purpose billing features.

Strong revenue cycle management ties these clinical and billing steps together so denials get caught and corrected quickly.

Conclusion

Bortezomib claims are high-value and high-scrutiny. HCPCS code J9041 applies specifically to Velcade; every other bortezomib product requires the manufacturer-specific code matching its NDC (J9046, J9048, J9049, or J9051), since J9044 was deleted at the end of 2022.

JW or JZ modifier attachment is mandatory per CMS policy. Dose-based unit calculation, NDC matching, and prior authorization documentation are the three most common failure points on these claims.

Pabau’s claims management tools help oncology billing teams structure their drug billing workflows, from administered dose capture through modifier attachment and claim submission. To see how Pabau supports infusion and oncology billing, book a demo with our team.

Continue your research

Need to track oncology drug billing across multiple locations? Claims management tools for multi-site practices help standardize modifier rules and drug unit tracking across your entire team.

Looking for structured clinical documentation for infusion visits? Digital forms in Pabau allow oncology teams to capture dose, route, and clinical data in structured fields that flow into billing records.

Want to understand how EHR data connects to billing workflows? EHR-to-billing integration guidance from Pabau explains how clinical and billing systems share data to reduce manual re-entry errors on high-cost drug claims.

Frequently asked questions